Company: SXTPW
Filing Date: 2025-07-16
Form Type: 424B4
Source: 0001213900-25-064472
Chunk: 7

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-16
Form: 424B4
Chunk 7
---
 which an anti-infective or other pharmaceutical product is known or suspected to affect a disease process. This process 
 is different for each drug and may or may not be known at the time of FDA approval.                                                    |

| ● | “NIH” means the National 
 Institutes of Health.    |

| ● | “RSV” means respiratory                                                                      
 syncytial virus, which is a common respiratory virus that usually causes cold-like symptoms. |

| ● | “Spp” is shorthand                                                                                                           
 use to refer to multiple species of organisms in a particular genus. Thus, Candida spp refers collectively to Candida auris, 
 Candida albicans and other Candida species.                                                                                  |

| ● | “Tafenoquine” is the                                                                   
 shortened name of the active ingredient of Arakoda and Kodatef, Tafenoquine succinate. |

<div align='center'>iii</div>

| ● | “TGA” is the Therapeutic                                    
 Goods Administration, the Australian equivalent of the FDA. |

| ● | “Zika” means a                                                            
 mosquito-borne viral disease occurring in tropical and subtropical areas. |

In connection with presentation of scientific
data, this prospectus references “P-values” at various points. These values are provided to convey the likelihood of
a particular set of data occurring by chance. For example, a P-value of 0.12 associated with a stand-alone, pre-conceived hypothesis
is generally understood to mean that the likelihood of that particular outcome occurring purely by chance is 12%. It is scientific convention
that a particular observation is “proven” if its associated P value is lower than 0.05 (i.e., associated with a likelihood
of occurring by chance of < 5%). However, clinical observations of interest are routinely reported in the peer-reviewed scientific
literature even if their associated P-values are > 0.05, because they may represent important therapeutic signals, and motivate
additional research.

<div align='center'>USE of PRODUCT VERSUS GENERIC NAMES</div>

This prospectus makes reference to two commercial
products owned/manufactured by 60P, Arakoda and Kodatef, which are approved by regulators in the United States and Australia, respectively,
for the prevention of malaria. The active molecule in those products is Tafenoquine succinate (Tafenoquine for short), which we are repositioning
for other indications using either (i) the same dosing regimen employed in the